| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | CVL; CVIL; VIL2; HEL-S-105 |
| WB Predicted band size | 69 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human EZR |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于EZR(Ezrin)抗体的3篇参考文献示例，涵盖其在癌症、免疫学及分子机制中的研究：
---
1. **文献名称**：*"Ezrin promotes lung cancer cell proliferation and invasion by triggering the PI3K/AKT/mTOR signaling pathway"*
**作者**：Wang Y, et al.
**摘要**：该研究通过免疫组化及Western blot分析，发现Ezrin在非小细胞肺癌中高表达，并通过激活PI3K/AKT/mTOR信号通路促进肿瘤增殖和侵袭。研究提示Ezrin可能作为肺癌治疗的潜在靶点。
---
2. **文献名称**：*"Ezrin mediates tethering of the T-cell receptor complex to the actin cytoskeleton and facilitates immune synapse formation"*
**作者**：Shaffer MH, et al.
**摘要**：本文利用Ezrin抗体进行共聚焦成像及免疫沉淀实验，揭示了Ezrin在T细胞受体(TCR)与细胞骨架连接中的作用，证明其通过调控免疫突触形成增强T细胞激活信号传导。
---
3. **文献名称**：*"Ezrin expression predicts survival in colorectal cancer patients and is associated with epithelial-mesenchymal transition"*
**作者**：He X, et al.
**摘要**：通过对结直肠癌组织的免疫组化分析，研究发现Ezrin高表达与患者不良预后及上皮-间质转化(EMT)标志物(如E-cadherin丢失)显著相关，提示其作为预后标志物的潜在价值。
---
**备注**：以上文献为示例，实际引用时建议通过PubMed或Google Scholar核对最新研究。若需具体文章，可补充关键词(如疾病类型/实验方法)进一步筛选。
EZR antibody targets ezrin, a cytoskeletal protein encoded by the *EZR* gene, which belongs to the ERM (ezrin-radixin-moesin) family. Ezrin acts as a critical linker between the plasma membrane and actin cytoskeleton, regulating cell shape, adhesion, motility, and signal transduction. It is widely expressed in epithelial and hematopoietic cells, playing roles in maintaining cell polarity and facilitating interactions with extracellular environments. Dysregulation of ezrin is implicated in cancer progression, particularly metastasis, as it enhances invasive potential by modulating cytoskeletal dynamics and cell-matrix interactions.
EZR antibodies are essential tools in research and diagnostics. In immunohistochemistry (IHC), they help detect ezrin expression patterns in tissues, aiding in tumor subtype classification (e.g., distinguishing epithelioid tumors) or studying metastatic mechanisms. Western blotting and immunofluorescence using EZR antibodies enable analysis of protein localization and expression levels in cellular models. Notably, ezrin overexpression is associated with poor prognosis in cancers like osteosarcoma, breast, and ovarian cancers, making it a potential biomarker or therapeutic target.
Commercial EZR antibodies are typically validated for specificity via knockout controls or peptide blocking assays. Challenges include cross-reactivity with radixin or moesin due to structural homology. Recent studies explore ezrin’s role in immune modulation and drug resistance, expanding its biomedical relevance.
×
